| Lori-ann R Wilcox, MD | |
|
13943 N 91st Ave, C-101, Peoria, AZ 85381-3687 | |
| (623) 760-9449 | |
| (623) 974-9351 |
| Full Name | Lori-ann R Wilcox |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 36 Years |
| Location | 13943 N 91st Ave, Peoria, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063470623 | NPI | - | NPPES |
| 1726808 | Other | AZ | UNITED HEALTHCARE |
| 188961600 | Other | AZ | DEPT OF LABOR WORK COMP |
| AZ0804410 | Other | AZ | BLUE CROSS BLUE SHIELD |
| WCKLL05 | Other | MEDICARE ID | |
| 1063470623 | Other | AZ | AHCCCS |
| 070010475 | Other | AZ | RAILROAD MEDICARE |
| 1017047 | Other | AZ | AETNA |
| 1Z3908 | Other | AZ | HEALTH NET |
| 99S007000009 | Other | AZ | MEDISUN |
| 379736 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 24876 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southwest Skin Specialists Llc | 9739079864 | 47 |
News Archive
A paper published in the current issue of P&P? tests the widely accepted assumption in drug trials: neither evaluators nor patients know whether the patient is getting drug or placebo (double blindness).
Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.
According to a new report up to 24,000 diabetes-related deaths could be avoided in England each year, if patients and doctors better managed the condition. This is the first-ever audit of patient deaths from diabetes. It says that basic health checks, a good diet and regular medication could prevent most of the deaths.
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
The president wants to phase out a Medicaid provider tax that Malloy has used to help balance his budget. The White House also wants to "blend" Medicaid rates with the rates received from the federal government for a health program for children. That could mean fewer federal health dollars for Connecticut.
› Verified 7 days ago
| Entity Name | Southwest Skin Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174521926 PECOS PAC ID: 9739079864 Enrollment ID: O20040319001063 |
News Archive
A paper published in the current issue of P&P? tests the widely accepted assumption in drug trials: neither evaluators nor patients know whether the patient is getting drug or placebo (double blindness).
Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.
According to a new report up to 24,000 diabetes-related deaths could be avoided in England each year, if patients and doctors better managed the condition. This is the first-ever audit of patient deaths from diabetes. It says that basic health checks, a good diet and regular medication could prevent most of the deaths.
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
The president wants to phase out a Medicaid provider tax that Malloy has used to help balance his budget. The White House also wants to "blend" Medicaid rates with the rates received from the federal government for a health program for children. That could mean fewer federal health dollars for Connecticut.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lori-ann R Wilcox, MD 13943 N 91st Ave, C-101, Peoria, AZ 85381-3687 Ph: (623) 760-9449 | Lori-ann R Wilcox, MD 13943 N 91st Ave, C-101, Peoria, AZ 85381-3687 Ph: (623) 760-9449 |
News Archive
A paper published in the current issue of P&P? tests the widely accepted assumption in drug trials: neither evaluators nor patients know whether the patient is getting drug or placebo (double blindness).
Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.
According to a new report up to 24,000 diabetes-related deaths could be avoided in England each year, if patients and doctors better managed the condition. This is the first-ever audit of patient deaths from diabetes. It says that basic health checks, a good diet and regular medication could prevent most of the deaths.
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
The president wants to phase out a Medicaid provider tax that Malloy has used to help balance his budget. The White House also wants to "blend" Medicaid rates with the rates received from the federal government for a health program for children. That could mean fewer federal health dollars for Connecticut.
› Verified 7 days ago
Deborah Zell, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13943 N 91st Ave, #c-1, Peoria, AZ 85381 Phone: 623-972-3992 Fax: 623-583-4074 | |
Mary F Fredenberg, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave, Suite #110, Peoria, AZ 85381 Phone: 623-215-0911 Fax: 623-215-0912 | |
Dr. Julie Jacobs, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave Ste 110, Peoria, AZ 85381 Phone: 623-888-8145 | |
Dr. Troy C Ellis, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 13943 N 91st Ave, #c-101, Peoria, AZ 85381 Phone: 623-760-9449 Fax: 623-974-9351 | |
Douglas Heiner, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 14155 N 83rd Ave Ste 110, Peoria, AZ 85381 Phone: 623-215-0911 | |
Dr. Rosemary Theresa Depaoli, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 7767 W Deer Valley Rd Ste 140, Peoria, AZ 85382 Phone: 623-487-3003 Fax: 623-889-7137 |